Condition: Multiple Myeloma · Primary Plasma Cell Leukemia · Extramedullary Multiple Myeloma · Sponsor: Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
This study will assess whether the combination of daratumumab and carfilzomib-based Induction/Consolidation/Maintenance Therapy with ASCT improves the outcome of patients with ultra high-risk, newly diagnosed multiple myeloma
This description comes directly from the study's public registry record.
Chunyan Sun, MD · +8602785726387 · suncy0618@163.com
Jian Xu, MD · +8602785726006 · xujian01222@163.com
Always discuss trial participation with your own doctor first.
| Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Wuhan, Hubei, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06140966